DENELSKY STEPHEN J 4

What Happened

• Stephen J. Denelsky, a director of Harvard Bioscience, was granted 16,556 restricted stock units (RSUs) on June 9, 2026. The award was recorded at $0.00 per share (no cash paid) — the grant itself has no immediate cash value but represents future equity if and when the units vest.

Key Details

• Transaction date and type: 2026-06-09 — Grant/Award (code A) of 16,556 RSUs at $0.00.
• Shares/units owned following the transaction: 37,556 total (per filing): 16,556 newly granted RSUs + 11,000 existing RSUs vesting 9/5/2026 + 10,000 common shares purchased 3/17/2026.
• Vesting: The 16,556 RSUs vest in full either immediately prior to the company’s next annual meeting or one year from the grant date, whichever is earlier (footnote F1).
• Reverse split: A 10-for-1 reverse split on 3/13/2026 adjusted previously reported RSU counts; the 11,000 RSUs in the filing reflect that adjustment (footnote F3).
• Filing timeliness: Reported on Form 4 filed 2026-06-11 for a 2026-06-09 transaction — appears timely under Form 4 rules.

Context

• This was an equity compensation grant (not a purchase or sale). Grants like RSUs are routine forms of director compensation and do not by themselves indicate the director bought or sold shares in the market.
• The awarded RSUs have future value tied to HBIO’s stock price if and when they vest and convert to shares; they are not immediate liquidity.